Check out other pages at BiotechDueDiligence for an intro to Complete Genomics GNOM as well as info on the GNOM merger with BGI and the role Illumina ILMN is playing in that deal. Continue reading below for relevant highlights from the ILMN 3q-2012 earnings conference call.
"Services and other revenue, which includes genotyping and sequencing services as well as instrument maintenance contracts, was $23 million for the quarter, an 8% increase sequentially and a 54% increase year-over-year.
Our FastTrack Services business had a very strong quarter. As Marc mentioned, we shipped more than twice as many samples in Q3 as we did in Q2 and achieved a new record for whole genome shipments. In addition, we continue to build our backlog, and ASPs for new orders significantly exceeds our expectations.
And so -- and what happens now that it looks like BGI is going to be purchasing another competitor of yours. I mean, what if that happen -- what did -- how does that change your relationship with BGI? I mean, how much of their work is being done as whole-human genome sequencing?
We don't know exactly. It's probably in the range of 10% to 20% would be our guess. As I said, we don't know that number for sure. We're in discussions with BGI to get a sense of where the relationship may go. As you're aware, that acquisition is not yet completed, and so they don't own the entity as yet. And it will be at least several more months before that happens, if it does. And so, at that point, we'll engage very directly with BGI in a conversation about how the relationship evolves.
Well, certainly, there will be continued investments in the diagnostics part of our business and the translational parts of our business. This will be for some clinical trial work in the diagnostics area. We are going to begin to put some test through the FDA beginning in the next few months, and that will continue through 2013. And each of those has probably in the range of $1 million to $3 million or $4 million worth of clinical trial expense associated with them.
Our FastTrack Services business had a very strong quarter. As Marc mentioned, we shipped more than twice as many samples in Q3 as we did in Q2 and achieved a new record for whole genome shipments. In addition, we continue to build our backlog, and ASPs for new orders significantly exceeds our expectations.
And so -- and what happens now that it looks like BGI is going to be purchasing another competitor of yours. I mean, what if that happen -- what did -- how does that change your relationship with BGI? I mean, how much of their work is being done as whole-human genome sequencing?
We don't know exactly. It's probably in the range of 10% to 20% would be our guess. As I said, we don't know that number for sure. We're in discussions with BGI to get a sense of where the relationship may go. As you're aware, that acquisition is not yet completed, and so they don't own the entity as yet. And it will be at least several more months before that happens, if it does. And so, at that point, we'll engage very directly with BGI in a conversation about how the relationship evolves.
Well, certainly, there will be continued investments in the diagnostics part of our business and the translational parts of our business. This will be for some clinical trial work in the diagnostics area. We are going to begin to put some test through the FDA beginning in the next few months, and that will continue through 2013. And each of those has probably in the range of $1 million to $3 million or $4 million worth of clinical trial expense associated with them.
RSS Feed
